Saskia Biskup
Managing Director CeGaT GmbH
Saskia Biskup, MD/PhD, is co-founder and (interim) managing director of cecava. After inventing the neoepitope vaccine technology, she applied it to patients suffering from tumors of various origins in her doctor’s office in the setting of individual treatment attempts. Building on this experience, she co-founded cecava with her husband, Dirk Biskup (PhD), to conduct clinical trials to ultimately prove the efficacy of this novel therapy and to enable its approval for the benefit of cancer patients.
Seminars
Thursday 19th February 2026
Advancing the Use of Cancer Vaccines in Glioblastoma to Reprogram the Patient’s Immune System
5:00 pm
- Designing vaccines to prime and activate the patient’s own immune system to recognize and attack specific GBM cells
- Identifying and utilizing GBM specific tumor antigens to develop targeted and effective vaccine strategies
- Focussing on GBM vaccines in combination with other modalities to overcome the TME and boost anti-tumor response
